Last quarter (Q4 2023), Gain Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Gain Therapeutics's net income was $-4.72M. See Gain Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 55.18K	$ 55.18K	$ 140.11K	$ 133.93K	$ 28.88K	$ 41.30K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 55.18K	$ 55.18K	$ 140.11K	$ 164.99K	-	-
Operating Expense	$ 22.31M	$ 22.31M	$ 17.92M	$ -13.99M	$ 3.51M	$ 2.14M
Operating Income	$ -22.25M	$ -22.25M	$ -17.78M	$ -13.83M	$ -3.48M	$ -2.10M
Net Non Operating Interest Income Expense	$ 342.20K	$ 494.23K	$ 375.36K	-	$ 3.64K	$ -20.54K
Other Income Expense	-	-	-	-	$ -96.48K	$ -65.68K
Pretax Income	$ -22.19M	$ -22.19M	$ -17.50M	$ -13.89M	$ -3.57M	$ -2.19M
Tax Provision	$ 79.28K	$ 79.28K	$ 92.98K	$ 4.01K	$ 5.39K	$ 7.11K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -22.27M	$ -22.27M	$ -17.59M	$ -13.89M	$ -3.58M	$ -2.19M
Basic EPS	$ -1.73	$ -1.71	$ -1.48	$ -1.37	$ -0.61	$ -0.37
Diluted EPS	$ -1.73	$ -1.71	$ -1.48	$ -1.37	$ -0.61	$ -0.37
Basic Average Shares	$ 52.05M	$ 13.01M	$ 11.88M	$ 10.17M	$ 5.86M	$ 5.86M
Diluted Average Shares	$ 52.05M	$ 13.01M	$ 11.88M	$ 10.17M	$ 5.86M	$ 5.86M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 22.31M	$ 22.31M	$ 17.92M	$ -13.99M	$ 3.51M	$ 2.14M
Net Income From Continuing And Discontinued Operation	$ -22.27M	$ -22.27M	$ -17.59M	$ -13.89M	$ -3.58M	$ -2.19M
Normalized Income	$ -13.48M	$ -17.53M	$ -13.82M	-	$ -3.51M	$ -2.15M
Interest Expense	-	-	-	-	-	-
EBIT	$ -22.68M	$ -22.68M	$ -17.87M	$ -13.90M	$ -3.48M	$ -2.10M
EBITDA	$ -22.60M	$ -22.60M	$ -17.81M	$ -13.88M	$ -3.47M	$ -2.10M

Currency in USD

Gain Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing